CLOs on the Move

Quentis Therapeutics

www.quentistx.com

 
Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.quentistx.com
  • 430 E 29th St Suite 1005
    New York, NY USA 10016
  • Phone: 646.440.9249

Executives

Name Title Contact Details

Similar Companies

Travere Therapeutics

At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife

Thermo Fisher Scientific

Thermo Fisher Scientific is an American supplier of scientific instrumentation, reagents and consumables, and software services.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.

Ideaya Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.